New AHIMA tool ready to help with accurate coding

With the clock ticking down on the Oct. 1 deadline to transition to the ICD-10 dataset, the American Health Information Management Association (AHIMA) has introduced a new tool to help providers succeed with the transition.

Launching on Oct. 12, AHIMA Code-Check is designed to offer expert interpretation and guidance on necessary pathways for accurate code assignment, guidelines for when to query for necessary documentation, identification of patient care variables that affect coding and more.

"AHIMA Code-Check doesn't just provide answers to questions but will show all the key steps for how the correct code was arrived at. It can be an important and ongoing source of continuing education," said AHIMA CEO Lynne Thomas Gordon in a press release.

AHIMA's credentialed members will be available to answer questions related to coding in several datasets, including ICD-10-CM and ICD-10-PCS, CPT and HCPCS. The service can be purchased on a subscription or as-needed basis.

The service's launch was scheduled to "coincide with the early days of the ICD-10 transition at the time when there is the biggest need for additional services and expertise around the new codeset."

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.